Why compounding is regulated: USP <795>, <797> and <800>
Objective. Explain the purpose of the three USP compounding chapters and the patient harm they are written to prevent, including the 2012 fungal-meningitis outbreak traced to a compounding pharmacy.
This lesson, its worked examples and its practice questions has not yet been verified by a licensed pharmacist or by a certification or approval body. It is a study draft and may contain errors. Do not use it to make decisions about any patient or medication. Always follow your instructor, your supervising professional, and current official references and regulations.
VoTechWorks program approval and accreditation are still in progress. Credentials are issued only by the certifying bodies named in each program, after their own exams.
Why Compounding Is Regulated
Most medications patients receive are manufactured in large batches by licensed drug manufacturers and approved by the Food and Drug Administration (FDA). However, some patients need medications that are not commercially available in the right dose, form, or ingredient combination. Compounding is the process of preparing a customized medication for a specific patient based on a licensed prescriber's order. Because compounded preparations are made in smaller quantities and are not subject to the same pre-market FDA approval process as commercially manufactured drugs, they carry unique risks — and those risks made federal and professional regulation necessary.
The 2012 Fungal Meningitis Outbreak
The clearest and most tragic demonstration of what can go wrong occurred in 2012. The New England Compounding Center (NECC), a compounding pharmacy in Massachusetts, produced injectable methylprednisolone acetate — a steroid injected into the spine to treat back pain. Contaminated lots of this preparation were shipped to clinics in multiple states. The contamination was later identified as the fungus Exserohilum rostratum, which does not normally cause disease but is deadly when introduced into the central nervous system.
By the time the outbreak was controlled, more than 750 patients had been infected with fungal meningitis and related infections, and more than 60 people died. Investigators found serious failures at the NECC: preparations were made without adequate sterility testing, environmental controls in the cleanroom were inadequate, and beyond-use dates were extended far beyond what was defensible. The outbreak led to federal legislation (the Drug Quality and Security Act of 2013) and dramatically increased enforcement attention on compounding pharmacies. It also illustrated why detailed, enforceable standards for sterile compounding are not optional — they are a matter of life and death.
United States Pharmacopeia (USP): Setting the Standards
The United States Pharmacopeia (USP) is a nonprofit organization that publishes legally recognized quality standards for medicines, dietary supplements, and compounding. Three general chapters govern pharmacy compounding practice in the US:
- USP Chapter <795> — Non-Sterile Preparations
- USP Chapter <797> — Sterile Preparations
- USP Chapter <800> — Hazardous Drugs
State boards of pharmacy and accreditation bodies reference these chapters when inspecting compounding facilities. Pharmacies that do not meet USP standards risk disciplinary action, closure, and — most importantly — patient harm.
USP <795>: Non-Sterile Compounding
USP <795> covers preparations that are not required to be sterile — creams, ointments, capsules, oral solutions, suppositories, and similar dosage forms. Its purpose is to ensure that a non-sterile compounded preparation has the correct identity, strength, and quality and will remain stable through its beyond-use date (BUD) — the date after which the preparation should not be used.
Key concerns addressed by <795> include:
- Choosing ingredients of appropriate quality
- Using proper equipment and documented procedures
- Assigning defensible beyond-use dates based on formulation and storage conditions
- Training and competency of compounding personnel
Harms prevented: incorrect drug concentration (too weak = therapeutic failure; too strong = toxicity), microbial contamination of oral or topical products, and physical or chemical instability that changes the dose the patient receives.
USP <797>: Sterile Compounding
USP <797> covers preparations that must be free of microbial contamination, pyrogens, and particulates because they bypass the body's normal defenses — they are injected, infused intravenously, administered into the eye, or inhaled. The 2012 NECC outbreak was a direct consequence of failing to meet the standards that <797> is designed to enforce.
<797> establishes requirements for:
- Primary Engineering Controls (PECs): Equipment such as laminar airflow workbenches or biological safety cabinets where the actual compounding of a compounded sterile preparation (CSP) takes place. Air in the PEC must meet strict cleanliness standards.
- Secondary Engineering Controls (SECs): The room (the cleanroom suite or segregated compounding area) that surrounds and supports the PEC. Temperature, humidity, air pressure, and particle counts must be controlled and monitored.
- Personnel garbing, hand hygiene, and competency (including media-fill tests and gloved fingertip sampling)
- Environmental monitoring: regular surface sampling and air sampling
- Beyond-use dating based on sterility category and storage conditions
- Finished preparation testing for sterility and endotoxins where required
Harms prevented: microbial contamination causing infection or sepsis, pyrogen-induced fever and shock, particulate matter causing emboli, and incorrect concentration causing overdose or underdose via injection.
USP <800>: Hazardous Drugs
USP <800> addresses a different dimension of risk: protecting the people who handle hazardous drugs (HDs) — substances that can cause cancer, reproductive harm, developmental harm, organ toxicity, or genotoxicity. Many chemotherapy agents fall into this category, as do some antiviral drugs, hormones, and other medications.
<800> applies to any facility that receives, stores, compounds, or dispenses hazardous drugs — not only pharmacies that compound. Its requirements include:
- Designating hazardous drug storage areas with negative-pressure ventilation
- Using appropriate personal protective equipment (PPE): chemotherapy-rated gloves, gowns, face protection
- Using a biological safety cabinet or compounding aseptic containment isolator (CACI) for compounding HDs
- Decontamination and cleaning procedures for surfaces and spill management
- Medical surveillance for personnel with routine HD exposure
Harms prevented: occupational exposure to carcinogens and reproductive toxins among pharmacy staff, nurses, and others who handle these drugs, and environmental contamination of the workplace.
The Three Chapters Together
Think of the three chapters as layers of protection. <795> safeguards non-sterile product quality. <797> adds the sterility dimension for injectable and other sterile routes. <800> overlays hazard controls wherever any hazardous drug is handled. A pharmacy compounding a sterile hazardous preparation — for example, an IV chemotherapy drug — must comply with all three chapters simultaneously.
Understanding these chapters is fundamental to safe compounding practice and is tested on both the PTCE and ExCPT.
Key terms9
Materials: USP chapter summaries
Check: Quiz ≥ 80%
Practice check8
Answer each question, then check it. Nothing is recorded; this is your own practice.
